

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAWWS1632

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 4 APR 04 STN AnaVist \$500 visualization usage credit offered
NEWS 5 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS 6 MAY 11 KOREAPAT updates resume
NEWS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAPLUS and
USPATFULL/USPAT2
NEWS 9 MAY 30 The F-Term thesaurus is now available in CA/CAPLUS
NEWS 10 JUN 02 The first reclassification of IPC codes now complete in
INPADOC
NEWS 11 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and
and display fields
NEWS 12 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL
NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
<http://download.cas.org/express/v8.0-Discover/>
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:12:40 ON 30 JUN 2006

=> FILE MEDLINE,CAPLUS,BIOSIS, EMBASE, SCISEARCH		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	1.05	1.05

FILE 'MEDLINE' ENTERED AT 11:15:49 ON 30 JUN 2006

FILE 'CAPLUS' ENTERED AT 11:15:49 ON 30 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 11:15:49 ON 30 JUN 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 11:15:49 ON 30 JUN 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 11:15:49 ON 30 JUN 2006
Copyright (c) 2006 The Thomson Corporation

=> S gp100
L1 2809 GP100

=> S avipox
L2 338 AVIPOX

=> S poxvirus
L3 11228 POXVIRUS

=> L1 AND L2 AND L3
L1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> S L1 AND L2 AND L3
L4 0 L1 AND L2 AND L3

=> S L1 AND L2
L5 0 L1 AND L2

=> S "T cell activating cytokine"
L6 43 "T CELL ACTIVATING CYTOKINE"

=> S L1 AND L6
L7 1 L1 AND L6

=> S L2 AND L6
L8 0 L2 AND L6

=> S L3 AND L6
L9 0 L3 AND L6

=> S T cell activating cytokine
L10 43 T CELL ACTIVATING CYTOKINE

=> S gene therapy
L11 162287 GENE THERAPY

=> S L1 AND L11
L12 125 L1 AND L11

=> S L6 AND L12
L13 0 L6 AND L12

=> S cytokine
L14 737027 CYTOKINE

=> S L14 AND L11 AND L1
L15 33 L14 AND L11 AND L1

=> S L14 AND L11 AND L1 AND L3
L16 1 L14 AND L11 AND L1 AND L3

=> D L15

L15 ANSWER 1 OF 33 MEDLINE on STN
AN 2005219788 MEDLINE
DN PubMed ID: 15853729
TI Cancer gene therapy utilizing interleukin-13 receptor
alpha2 chain.
AU Kawakami Koji
CS Laboratory of Molecular Tumor Biology, Division of Cellular and Gene
Therapies, Center for Biologics Evaluation and Research, Food and Drug
Administration, Bethesda, MD, USA.. kawakami-k@umin.ac.jp
SO Current gene therapy, (2005 Apr) Vol. 5, No. 2, pp. 213-23. Ref: 123
Journal code: 101125446. ISSN: 1566-5232.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200506
ED Entered STN: 29 Apr 2005
Last Updated on STN: 1 Jul 2005
Entered Medline: 30 Jun 2005

=> D ti,abs L15 1-33

L15 ANSWER 1 OF 33 MEDLINE on STN
TI Cancer gene therapy utilizing interleukin-13 receptor
alpha2 chain.
AB Cancer cells are known to express cell surface molecules such as specific
antigens or cytokine receptors, e.g., EGFR, Fas/CD95,
gp100, HER-2/neu, IL-13Ralpha2, and MAGE. Among them,
interleukin-13 receptor (IL-13R) alpha2 chain is expressed on certain
types of cancer cells including glioblastoma, AIDS Kaposi's sarcoma, and
head and neck cancer. This protein is one of the receptor components for
IL-13, a Th2 cell-derived pleiotropic immune regulatory cytokine
. IL-13Ralpha2 chain on these cancer cells can be targeted with a
receptor-directed cytotoxin termed IL13-PE to induce specific cancer cell
killing, however, this molecule does not mediate cytotoxicity to cells
that do not express or express low levels of IL-13Ralpha2. In order to
achieve a broad therapeutic window for IL13-PE, plasmid-mediated gene
transfer of IL-13Ralpha2 in cancer cells was employed in vitro and in
vivo. Cancer cells transfected with IL-13Ralpha2 demonstrated increased
binding to IL-13 and sensitivity to IL13-PE in vitro. In vivo
intratumoral gene transfer of IL-13Ralpha2 profoundly enhanced the
antitumor activity of IL13-PE, providing complete elimination of
established tumor in some xenografts. In this review article, current
findings from IL-13Ralpha2 gene transfer in a variety of human cancer
models in nude mice are summarized. In addition, safety issues and
possible future directions utilizing this therapeutic approach are
discussed.

L15 ANSWER 2 OF 33 MEDLINE on STN
TI Biased epitope selection by recombinant vaccinia-virus (rVV)-infected
mature or immature dendritic cells.
AB Recombinant expression vectors represent a powerful way to deliver whole
antigens (Ags) for immunization. Sustained Ag expression in
vector-infected dendritic cells (DC) combines Ag-specific stimulation with
powerful costimulation and, simultaneously, through 'self-selection' of ad
hoc epitopes broadens the scope of immunization beyond restrictions posed
by individual patients' human leukocyte antigen (HLA) phenotype. In this
study, therefore, we evaluated the efficiency of a recombinant vaccinia
virus encoding the gp100/PMel17 melanoma Ag (rVV-gp100
) to infect immature (iDC) or mature dendritic cells (mDC) derived from